Prefer Divis Labs, Aurobindo Pharma: Harendra Kumar

Harendra Kumar of Elara Capital told CNBC-TV18, "Midcap pharmaceuticals posted some stellar numbers and the valuation gap in some of the large pharmaceutical companies is extremely wide. Divis Laboratories, Torrent Pharmaceuticals and Aurobindo Pharma did extremely well. I think they will continue to do well in the run up to the next quarterly numbers and that is where one should be positioned in."

At 10:23 hrs Aurobindo Pharma was quoting at Rs 507.60, up Rs 3.70, or 0.73 percent. It has touched an intraday high of Rs 510 and an intraday low of Rs 503.10.

The share touched its 52-week high Rs 536 and 52-week low Rs 127.15 on 07 February, 2014 and 28 March, 2013, respectively. Currently, it is trading 5.3 percent below its 52-week high and 299.21 percent above its 52-week low. Market capitalisation stands at Rs 14,788.36 crore.